SGLT2 inhibitor therapy for transthyretin amyloid cardiomyopathy: early tolerance and clinical response to dapagliflozin

AIMS: Sodium‐glucose cotransporter 2 inhibitors (SGLT2i) improve clinical outcomes in heart failure patients with reduced and preserved left ventricular ejection fraction (LVEF), but have not yet been investigated in transthyretin amyloid cardiomyopathy (ATTR‐CM). This study aimed to evaluate tolera...

Descripción completa

Detalles Bibliográficos
Autores principales: Dobner, Stephan, Bernhard, Benedikt, Asatryan, Babken, Windecker, Stephan, Stortecky, Stefan, Pilgrim, Thomas, Gräni, Christoph, Hunziker, Lukas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9871707/
https://www.ncbi.nlm.nih.gov/pubmed/36259276
http://dx.doi.org/10.1002/ehf2.14188

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9871707/
https://www.ncbi.nlm.nih.gov/pubmed/36259276
http://dx.doi.org/10.1002/ehf2.14188

Ejemplares similares